CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Thomas Stephen Basil Director | Sale 10b5-1 | −100,000 | $13.67 | $1.4M | 467,969 |
| 2026-06-29 | Brennan Aoife President and CEO | Sale 10b5-1 | −30,902 | $13.17 | $407K | 87,731 |
| 2026-02-26 | Thomas Stephen Basil Director | Sale 10b5-1 | −16,313 | $7.01 | $114K | 154,657 |
| 2026-02-25 | Thomas Stephen Basil Director | Sale 10b5-1 | −33,687 | $7.00 | $236K | 170,970 |
| 2026-02-13 | Thomas Stephen Basil Director | Sale 10b5-1 | −10,000 | $5.81 | $58K | 204,657 |
| 2026-02-12 | Thomas Stephen Basil Director | Sale 10b5-1 | −90,000 | $5.23 | $471K | 214,657 |
| 2025-06-30 | Brennan Aoife President and CEO | Sale 10b5-1 | −20,618 | $1.22 | $25K | 48,132 |
| 2025-06-20 | Pimblett Emily SVP, Finance & CAO | Sale 10b5-1 | −1,242 | $1.24 | $2K | 18,888 |
| 2025-03-20 | Pimblett Emily SVP, Finance & CAO | Sale 10b5-1 | −1,199 | $1.31 | $2K | 15,130 |
| 2024-12-19 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,235 | $2.02 | $2K | 11,329 |
| 2024-09-20 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −1,182 | $8.18 | $10K | 7,573 |
| 2024-09-20 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −9 | $8.06 | $73 | 7,564 |
| 2024-07-22 | Morisset Valerie EVP, R&D AND CSO | Sale | −39,005 | $8.07 | $315K | 61,317 |
| 2024-07-22 | Morisset Valerie EVP, R&D AND CSO | Sale | −30,000 | $7.98 | $239K | 31,317 |
| 2024-07-19 | Morisset Valerie EVP, R&D AND CSO | Sale | −10,201 | $7.09 | $72K | 150,322 |
| 2024-07-19 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.24 | $362K | 100,322 |
| 2024-07-18 | Morisset Valerie EVP, R&D AND CSO | Sale | −38,576 | $6.93 | $267K | 160,523 |
| 2024-07-17 | Morisset Valerie EVP, R&D AND CSO | Sale | −3,207 | $6.91 | $22K | 199,099 |
| 2024-07-16 | Morisset Valerie EVP, R&D AND CSO | Sale | −50,000 | $7.13 | $357K | 202,306 |
| 2024-07-15 | Morisset Valerie EVP, R&D AND CSO | Sale | −42,377 | $7.01 | $297K | 252,306 |
Page 1 of 2 · 27 trades